Company Update (NYSE:PFE): Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis

[Business Wire] – Pfizer Inc. announced today detailed results from the Oral treatment Psoriasis Trial Retreatment study , a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic . . . → Read More: Company Update (NYSE:PFE): Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis Similar Articles: Pfizer Inc (NYSE:PFE) – Pfizer Hosts Annual Meeting of Shareholders Declares 26-Cent Second-Quarter 2014 Dividend Pfizer Inc (NYSE:PFE) – Pfizer Invites Public to Listen to Webcast of April 24 Annual Meeting of Shareholders Pfizer Inc (NYSE:PFE) – Pfizer Announces FDA Approval to Include Radiographic Data on Reduction of Progression of Structural Joint Damage for Adults with Moderately to Severely Active Rheumatoid Arthritis in Labeling for XELJANZ® (tofacitinib citrate)